Morgan Stanley Lifts Price Targets on Jazz Pharmaceuticals and Neurocrine
Morgan Stanley raised its price target on Jazz Pharmaceuticals to $324 and on Neurocrine to $191, keeping both ratings unchanged. Reported by Dow Jones Newswires, citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley raised its price target on Jazz Pharmaceuticals (JAZZ) to $324 from $319 and kept its Overweight rating. Dow Jones Newswires reported the move, citing Benzinga.
For Neurocrine (NBIX), the bank lifted its target to $191 from $185 and maintained an Equal-Weight rating. Both changes were recorded on November 13, 2026, around 18:00 GMT.
why it matters
Price target revisions reflect one analyst's view and rarely move the broader market on their own. Investors typically focus more on company results and the overall sentiment in the pharmaceutical sector.
tags
instruments
on polymarket
sources
- Jazz Pharmaceuticals Price Target Raised to $324.00/Share From $319.00 by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 18:01 UTC
- Neurocrine Price Target Raised to $191.00/Share From $185.00 by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 18:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗